BTN3A2 and neoplasm: In addition, in many tumor models, high expression of BTN3A in tissues and high levels of soluble BTN3A2 and BTN2A in plasma can be used as markers of the efficacy of Vγ9Vδ2 T-cell immunotherapy [65, 146–151].